BioPharma Dive - Latest News

Sanofi licenses immune disease drugs from startup Earendil

The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at multiple popular immune disease targets, such as TL1A and IL23. 

Apr 17, 2025 - 16:26
 0
Sanofi licenses immune disease drugs from startup Earendil

The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at multiple popular immune disease targets, such as TL1A and IL23. 

Read More

Tags:

Previous Article

FDA clears Precision Neuroscience’s minimally invasive brain-computer interface ...

Next Article

STAT+: GSK blood cancer therapy, once pulled from the market, is approved in the...

Related Posts

Alcon buys majority stake in IPO-seeking cell therapy startup Aurion

Alcon buys majority stake in IPO-seeking cell therapy s...

Mar 27, 2025  0

Tempero Bio gets $70M to advance substance abuse treatment

Tempero Bio gets $70M to advance substance abuse treatment

Mar 24, 2025  0

Optum Rx says it will eliminate some prior authorization requirements

Optum Rx says it will eliminate some prior authorizatio...

Mar 19, 2025  0